Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947672 | 1.00 | TLR7 (0.66) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27238439 | 0.91 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL30824667 | 0.91 | TLR7 (0.57) | TLR7TLR8 | |
| SCHEMBL27238453 | 0.86 | TLR7 (0.54) | TLR7TLR8 | |
| SCHEMBL29947634 | 0.84 | TLR7 (0.75) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29136664 | 0.84 | TLR7 (0.75) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5364616 | 0.82 | TLR7 (0.48) | TLR7 | |
| SCHEMBL25962881 | 0.81 | TLR7 (0.49) | TLR7 | |
| SCHEMBL25950637 | 0.81 | TLR7 (0.42) | TLR7PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25950619 | 0.80 | TLR7 (0.44) | TLR7PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | TLR7 1/4885PDE4A 512/4885PDE4B 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.